Urinary Tract infection (UTI) is the most common bacterial infection caused by a wide range of pathogens such as Escherichia coli, Klebsiella pneumonia, proteus miravillis, Enterococcus faecalis, and staphylococcus saprophytic. These bacteria are mainly responsible for the infection of the urinary tract. Uncomplicated urinary tract infection is most common in young women who are sexually active with a normal unobstructed genitourinary tract, and no instrument implant history.
The Uncomplicated Urinary Tract Infection medication demand is anticipated to expand into the growth quadrant over the next decade, thanks to an inflow of pharma firms striving to develop innovative medicinal agents and gain a significant portion of the UTI industry. GlaxoSmithKline, Fimbrion Therapeutics, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, and others are developing innovative treatments to propel the Uncomplicated Urinary Tract Infection market ahead.
In the crucial study, Sulopenem is presently targeting the quinolone non-susceptible pool. In the SURE-2 phase 3 clinical study of oral and IV sulopenem in severe urinary tract infection, sulopenem previously failed to meet the primary goal (cUTI). However, now that SURE-1 has met its primary aim, Iterum Therapeutics has discovered a group (Quinolone non-susceptible UTI) in which the medication appears to work and might be approved. The FDA is presently reviewing oral sulopenem for uncomplicated urinary tract infections in patients with quinolone-intolerant pathogens, with a PDUFA goal date of July 25, 2021.
The Asia Pacific is estimated to gain significant attraction in the forecast timeframe due to the growing healthcare industry and innovations in drug molecules. Further, a growing amalgamation of drug molecules and clinical trials on adverse drug reactions is likely to boost the regional market. China is likely to lead in Asia pacific due to dominance of the chemical industry and increasing clinical trials in the region followed by innovation in novel drugs.
Despite a huge decline in the sales of products during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 4.1%, during the tenure of 2021 – 2027.
The report published by Maximize encompasses the market dynamics, which could affect the market growth of Urinary Tract Infections Therapeutics in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Urinary Tract Infections Therapeutics market at a global level the study is associated based on major segments and further into sub-segments, by Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, NitrofuransOther Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline) and Indications (Complicated UTI, Uncomplicated UTI, Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2020, considering 2020 as the base year.
Lastly, the market research report provides a regional comparison and a complete country- Allergan, Bayer AG, Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Lupin Ltd., Merck & Co., Inc (Merck Sharp & Dohme Corp), Dr. Reddy’s Laboratories Ltd., Almirall, S.A., Cipla, Shionogi and Co., Ltd, Abbott Laboratories, AbbVie Inc., Boehringer Ingelheim International GmbH.
You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Urinary Tract Infections Therapeutics Market.”
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051,
Maharashtra, India.
+91 9607195908